Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orexia Limited
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
The data compares the sensitivity of almost 200 diagnostics against a standardized set of samples.
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.
- Other Names / Subsidiaries
- Centessa Pharmaceuticals